751 related articles for article (PubMed ID: 33456560)
1. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
2. MicroRNA 452 regulates IL20RA-mediated JAK1/STAT3 pathway in inflammatory colitis and colorectal cancer.
Lamichhane S; Mo JS; Sharma G; Choi TY; Chae SC
Inflamm Res; 2021 Aug; 70(8):903-914. PubMed ID: 34283251
[TBL] [Abstract][Full Text] [Related]
3. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Gao R; Li D; Xun J; Zhou W; Li J; Wang J; Liu C; Li X; Shen W; Qiao H; Stupack DG; Luo N
Theranostics; 2018; 8(22):6248-6262. PubMed ID: 30613295
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
[TBL] [Abstract][Full Text] [Related]
5. Esculentoside A suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway.
Liu C; Dong L; Sun Z; Wang L; Wang Q; Li H; Zhang J; Wang X
Phytother Res; 2018 Nov; 32(11):2299-2311. PubMed ID: 30080291
[TBL] [Abstract][Full Text] [Related]
6. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis.
Shen W; Zhang X; Tang J; Zhang Z; Du R; Luo D; Liu X; Xia Y; Li Y; Wang S; Yan S; Yang W; Xiang R; Luo N; Luo Y; Li J
Theranostics; 2021; 11(5):2297-2317. PubMed ID: 33500726
[No Abstract] [Full Text] [Related]
7. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract][Full Text] [Related]
8. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
[TBL] [Abstract][Full Text] [Related]
9. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells.
Ciccone V; Terzuoli E; Donnini S; Giachetti A; Morbidelli L; Ziche M
J Exp Clin Cancer Res; 2018 Dec; 37(1):311. PubMed ID: 30541574
[TBL] [Abstract][Full Text] [Related]
10. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
[No Abstract] [Full Text] [Related]
13. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling.
Giordano M; Decio A; Battistini C; Baronio M; Bianchi F; Villa A; Bertalot G; Freddi S; Lupia M; Jodice MG; Ubezio P; Colombo N; Giavazzi R; Cavallaro U
J Exp Clin Cancer Res; 2021 Oct; 40(1):319. PubMed ID: 34645505
[TBL] [Abstract][Full Text] [Related]
14. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
16. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
17. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
18. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
19. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
20. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
